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a b s t r a c t
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase
2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome
received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% response
rate with an additional 49% stable disease, 34% transfusion independence) included 1 complete response
lasting 41 year. No responses were observed in MDS patients. Adverse events 430% included diarrhea,
fatigue, nausea, febrile neutropenia, and stomatitis. Results suggest modest activity in AML, supporting
further research to better understand how AAK inhibition may induce leukemic cell senescence.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The Aurora kinases are serine/threonine protein kinases essen-
tial for regulation of normal cell cycle mitosis. Aurora kinases
A (AAK) and B are overexpressed in hematologic malignancies,
including acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS); reduction of intracellular AAK results in mitotic
inhibition, senescence, and apoptosis in human cell lines [1].
Alisertib (MLN8237) is an investigational, orally available,
selective, small-molecule AAK inhibitor [1] with antitumor activity
in preclinical leukemia models [2,3].
Here we report an exploratory phase 2 trial of alisertib in a
heterogeneous patient population with AML or high-grade MDS
(NCT00830518). The single-agent alisertib regimen administered
in this study was determined by prior phase 1 studies [4,5].
2. Methods
AML patients ineligible for potentially curative treatment
options, with 410% bone marrow (BM) or peripheral blood blasts
at relapse, and who had failed to achieve complete response (CR)
or relapsed after prior therapy were eligible. High-grade MDS
patients were deﬁned as follows: (a) International Prognostic
Staging System (IPSS) risk Intermediate-2 or High; (b) 410% BM
blasts; and (c) treatment failure from, or not a candidate for,
standard therapies. Patients were aged Z18 years, with ECOG
performance status 0–2, and adequate hepatic and renal function.
The study was conducted according to the Declaration of
Helsinki and Good Clinical Practice. Review boards at all partici-
pating institutions approved the study protocol and all patients
provided written informed consent.
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In this open-label, phase 2 study, conducted in the USA,
Canada, and France, patients received alisertib 50 mg BID for
7 days plus 14-days' rest in 21-day cycles until disease progression
or unacceptable toxicity.
Response was evaluated per AML and MDS International Work-
ing Group (IWG) criteria [6,7]. Primary endpoint was overall
response rate (ORR; CR plus partial response [PR]). ‘CR’ included
CR with incomplete blood count recovery (per IWG guidelines) in
AML patients and marrow CR in MDS patients; ‘PR’ included
incomplete blood count recovery in AML and MDS patients [6,7].
Secondary endpoints included progression-free survival (PFS),
duration of response (DOR), and hematologic improvement in
MDS patients. The response-evaluable population for the primary
endpoint analysis included patients who received Z1 dose of
alisertib and had Z1 post-baseline response assessment. Safety
and tolerability were monitored throughout. Adverse events (AEs)
were graded by NCI CTCAE v3.0. The safety population included
patients who received Z1 dose of alisertib.
A Simon optimal 2-stage design was used, with 21 patients
enrolled in the ﬁrst stage and Z2 responses required to proceed
to the second stage. Sample size was estimated using a 1-sided test
at the signiﬁcance level of α¼0.05, power of 90%, a null hypothesis
of response rate r5%, and an alternative hypothesis of response
rate Z20%. To obtain 41 response-evaluable patients, enrollment
of 44 patients was projected. Time-to-event data were analyzed
by Kaplan–Meier methodology.
3. Results
Fifty-seven patients were enrolled (Table 1). The median
number of treatment cycles received was 2 (range 1–26) with
similar medians for AML and MDS. The maximum number of
cycles received for AML and MDS patients was 26 and 6, respec-
tively, with differences between diseases driven by an increased
response rate in AML patients.
Forty-ﬁve patients were response-evaluable; 12 were not due
to lack of on-study response assessment. ORR for the study was
13% (response-evaluable patients). Two responses were documen-
ted in stage 1; therefore, the study continued to stage 2. Recruit-
ment continued beyond the expected 44 patients in order to enroll
8 MDS patients.
3.1. Response – AML
Thirty-ﬁve AML patients were response-evaluable; 6 responded
(CR, n¼1; PR, n¼5; Table 2) giving an ORR of 17%. Four of the
6 responders had a history of prior MDS. DORs for responders
were 21n [asterisks denote censored observations], 27n, 57, 91n,
409, and 596 days, respectively, including 1 patient with durable
CR through 16 cycles (1 year). Seventeen patients (49%) had
stable disease. Time to ﬁrst response was 1–4 cycles. Changes in
blasts in responding patients shown in Fig. 1. There was no
apparent pattern of response according to AML subtype based
on the IWG recommended classiﬁcations (Table 2).
Twelve of 35 AML patients (34%) achieved transfusion inde-
pendence during the study; 10 maintained independence for Z2
cycles, and 1 for Z4 cycles.
Median PFS was 55 days (95% CI: 47, 67 days; range 1n–638).
Table 1
Patient demographics and baseline characteristics.
n (%) AML
(n¼46)
MDS
(n¼11)
Total
(N¼57)
Median age, years (range) 72 (48–83) 72 (46–85) 72 (46–85)
Male 24 (52) 8 (73) 32 (56)
White 36 (78) 10 (91) 46 (81)
Primary diseasea 25 (54) 10 (91) 35 (61)
Secondary disease 21 (46) 1 (9) 22 (39)
Prior history of MDS 18 (39) – –
IPSS score
Intermediate-2 (1.5 or 2.0) – 8 (73) –
High (Z2.5) – 3 (27) –
ECOG PS 0/1/2, n 9/29/8 3/8/0 12/37/8
Extramedullary disease 3 (7) 0 3 (5)
Median time since diagnosis, years 0.31 0.50 0.33
Classiﬁcation of AML
AML with recurrent genetic
abnormalitiesb
1 (2) – –
AML with multilineage dysplasiab,c,d 21 (46) – –
AML, therapy-relatedc 3 (7) – –
AML not otherwise categorized 24 (52)
AML minimally differentiated 4 (9) – –
AML without maturation 1 (2) – –
AML with maturationb 11 (24) – –
Acute myelomonocytic leukemia 4 (9) – –
Acute erythroid leukemia 1 (2) – –
Acute megakaryoblastic leukemia 1 (2) – –
Other 2 (4) – –
Prior therapy 39 (85) 10 (91) 49 (86)
Azacitidine 19 (41) 6 (55) 25 (44)
Cytarabine 22 (48) 3 (27) 25 (44)
Decitabine 14 (30) 4 (36) 18 (32)
Idarubicin 12 (26) 1 (9) 13 (23)
Allogeneic/autologous transplant 3 (7)f 0 3 (5)
Radiation therapy 2 (4) 1 (9) 3 (5)
Z3 prior therapies 8 (17) 1 (9) 9 (16)
Best response to prior therapy (n) 39 10 49g
CR 9 (23) 1 (10) 10 (20)
PR 4 (10) 0 4 (8)
SD 11 (28) 2 (20) 13 (27)
Median time since progression, months 1.3 1.0 1.1
AML, acute myeloid leukemia; CR, complete response; ECOG PS, Eastern Coopera-
tive Oncology Group performance status; IPSS, International Prognostic Staging
System; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; PR,
partial response; and SD, stable disease.
a Modiﬁed World Health Organization criteria at the time of primary diagnosis.
b 1 patient was classiﬁed as having AML with recurrent genetic abnormalities,
AML following MDS or MDS/MPD, and AML with maturation.
c 1 patient was classiﬁed as having AML, therapy related and AML following
MDS or MDS/MPD.
d 18 AML patients had multilineage dysplasia following MDS or MDS/MPD,
while the remaining 3 patients with multilineage dysplasia were without ante-
cedent MDS or MDS/MPD but had dysplasia in Z50% of cells in 1 or more myeloid
lineage.
f 2 patients had prior allogeneic transplant.
g 21 patients had progressive disease and response was not evaluable in
1 patient.
Table 2
Investigator-assessed best response in response-evaluable patients receiving
alisertib.
AML MDS Total
n (%) (n¼35) (n¼10) (N¼45)
ORR (CRþPR) 6 (17) 0 6 (13)
CR 1 (3)a 0 1 (2)
PR 5 (14)b 0 5 (11)
SD 17 (49) 2 (20) 19 (42)
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete
response; PR, partial response; and SD, stable disease.
a The patient with CR had AML with multilineage dysplasia.
b 5 patients with PR had AML with multilineage dysplasia (n¼2), or AML not
otherwise categorized (n¼3) which included acute myelomonocytic leukemia
(n¼1), acute megakaryoblastic leukemia (n¼1), and other: post-MDS (n¼1).
Two patients transformed from MDS to AML during the study – 1 patient
transformed before the ﬁrst response assessment (counted as AML), and the other
transformed at the second response assessment (counted as MDS).
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3.2. Response – MDS
None of 10 response-evaluable MDS patients responded;
1 patient achieved transfusion independence, maintained for at
least 2 cycles.
Median PFS was 38 days (95% CI: 35, 113; range 22n–113).
3.3. Safety
All patients experienced Z1 AE (Table 3). Drug-related grade
Z3 AEs were reported in 26 patients (46%; n¼19 AML, n¼7 MDS).
Serious AEs were documented in 44 patients (77%; drug-related in
n¼15, 26%). Fourteen patients (25%) discontinued due to AEs.
Fig. 1. Percentage change in bone marrow blasts from baseline over time (21-day cycles) in responding patients; plot lines represent individual patients (n¼6).
Table 3
Non-hematologic (Z15% all grades) and hematologic AEs.
Non-hematologic AEs (N¼57)
n (%) All grades Grade Z3
Treatment emergent Drug related Treatment emergent Drug related
Diarrhea 23 (40) 18 (32) 1 (2) 1 (2)
Fatigue 22 (39) 15 (26) 8 (14) 4 (7)
Nausea 22 (39) 13 (23) 0 0
Stomatitis 18 (32) 9 (16) 4 (7) 2 (4)
Somnolence 14 (25) 11 (19) 3 (5) 2 (4)
Abdominal pain 14 (25) 2 (4) 1 (2) 0
Dyspnea 14 (25) 1 (2) 6 (11) 1 (2)
Pyrexia 12 (21) 0 0 0
Peripheral edema 12 (21) 0 1 (2) 0
Cough 12 (21) 0 0 0
Alopecia 11 (19) 9 (16) 0 0
Asthenia 10 (18) 5 (9) 4 (7) 3 (5)
Vomiting 10 (18) 5 (9) 0 0
Sepsis 9 (16) 1 (2) 9 (16) 1 (2)
Hematologic AEs (N¼57)
n (%) All grades Grade Z3
AML (n¼46) MDS (n¼11) AML (n¼46) MDS (n¼11)
Treatment
emergent
Drug
related
Treatment
emergent
Drug
related
Treatment
emergent
Drug
related
Treatment
emergent
Drug
related
Febrile neutropenia 17 (37) 8 (17) 4 (36) 1 (9) 12 (26) 5 (11) 4 (36) 1 (9)
Anemia 14 (30) 4 (9) 3 (27) 1 (9) 10 (22) 4 (9) 1 (9) 1 (9)
Thrombocytopenia 9 (20) 3 (7) 2 (18) 2 (18) 7 (15) 3 (7) 2 (18) 2 (18)
Neutropenia 5 (11) 2 (4) 3 (27) 2 (18) 5 (11) 2 (4) 2 (18) 2 (18)
Leukopenia 3 (7) 1 (2) 2 (18) 2 (18) 2 (4) 0 2 (18) 2 (18)
Neutrophil count
decreased
3 (7) 3 (7) 0 0 3 (7) 3 (7) 0 0
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; and AE, adverse events.
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There were 22 on-study deaths (20 AML; 2 MDS), including 10
deaths prior to cycle 2. All deaths were considered unrelated to
alisertib; causes were progressive disease (n¼10, 46%), sepsis
(n¼5, 23%), cerebral/intracranial hemorrhage (n¼2, 9%), gastro-
intestinal infection, multi-organ failure, respiratory failure, renal
failure, and subdural hematoma (each n¼1, 5%).
4. Discussion
These results suggest that alisertib has modest single-agent
anti-leukemic activity, demonstrating a 13% ORR. Six responses
(17% ORR) were observed among AML patients, all of whom had
pre-treated disease. An additional 49% of AML patients achieved
stable disease, indicating a potentially clinically beneﬁcial effect.
Responses were generally observed by cycle 4 rather than during
cycle 1, suggesting that, in the absence of disease progression,
multiple cycles may be necessary to achieve anti-leukemic activity.
Overall median PFS in this study was 51 days.
The population in this exploratory phase 2 trial primarily
consisted of patients with progressive disease, including 21
patients (43%) refractory to most recent prior therapy and 3 having
failed prior transplant (2 allogeneic). Improved clinical outcomes
with alisertib may be possible in more selected populations, such
as those without refractory disease and those robust enough to
receive adequate drug to be effective.
The lack of response in MDS patients compared with AML
patients may point to important clues in alisertib clinical mechan-
ism of action. Failure of hematopoeisis in MDS is principally driven
by increased apoptosis in the malignant clone, in contrast to
marrow suppression by a proliferative clone in AML. In-vitro
studies have shown that reduction of intracellular AAK results in
mitotic inhibition, senescence, and apoptosis in human cell lines
[1]. Thus, alisertib may be unable to stimulate an apoptotic clone
in MDS but may suppress a proliferative clone in AML.
Transfusion independence was achieved in 13 patients and
maintained for 2–5 cycles in 11 patients, suggesting that recovery
of normal hematopoiesis can occur. Additional studies are needed
to identify predictors of response and to understand how AAK
inhibition may induce leukemic cell senescence, a property
described with preclinical model systems [8], which may comple-
ment an antimitotic effect. In conclusion, alisertib demonstrated
modest single-agent anti-leukemic activity, mostly limited to AML
patients in this study. The toxicity proﬁle was generally acceptable,
and consistent with expected effects of Aurora kinase inhibition in
proliferative tissues [9,10]. To allow for potentially delayed treat-
ment effects by alisertib, improved clinical outcomes in larger
populations will likely require additional strategies to enable early
disease control. Results of this study of alisertib in AML/MDS
highlight the need to develop predictors of response, combination
regimens, and other strategies to enhance the clinical utility of
treatment with this novel AAK inhibitor.
Role of the funding source
Research funded by Takeda Pharmaceuticals International Co.;
alisertib was manufactured and supplied by Takeda Pharmaceu-
ticals International Co. The sponsor declares a role in the study
design, collection and analysis of data, as reﬂected by the inclusion
of company authors. The ﬁnal decision to submit the manuscript
for publication lay solely with the authors.
Contributions
SLG, PF, MDC, EG, JL, JK, AP, GJS, and PW recruited and treated
patients. JJ, EJL, and HF participated in study design and data
collation. All authors participated in the preparation of the manu-
script and approval of the ﬁnal version to be submitted.
Conﬂicts of interest
Employment: HF, EJL, JJ (Takeda Pharmaceuticals International Co.).
Research Funding: SLG (Millennium: The Takeda Oncology
Company); EG (Amgen, Janssen-Cilag, Celgene); GJS (Millennium:
The Takeda Oncology Co.); PF (Celgene, Janssen-Cilag, Amgen,
Roche, GSK, Novartis, Merck, Cephalon).
Honoraria: EG (Janssen, Celgene); PW (Novartis, speakers
bureau); PF (Celgene, Janssen-Cilag, Amgen,Roche, GSK, Novartis,
Merck, Cephalon).
Membership: MDC (Genentech).
AP, JK, JL have no conﬂicts of interest to disclose.
Acknowledgments
The authors would like to thank the patients who participated
in this study and their families. The authors would also like to
acknowledge the writing assistance of Stephen Mosley, Ph.D., of
Knowledge Point 360, in the development of this manuscript,
which was funded by Millennium: The Takeda Oncology Company,
and Jeff Klko, MD, for providing photomicrographs.
References
[1] Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al.
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of
Aurora A kinase. Proc Natl Acad Sci USA 2007;104:4106–11.
[2] Kelly KR, Ecsedy J, Medina E, Mahalingham D, Padmanabhan S, Nawrocki ST,
et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant
chronic myeloid leukaemia and signiﬁcantly increases the efﬁcacy of nilotinib.
J Cell Mol Med 2011;15:2057–70.
[3] Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, et al.
Targeting Aurora A kinase activity with the investigational agent alisertib
increases the efﬁcacy of cytarabine through a FOXO-dependent mechanism.
Int J Cancer 2012;131:2693–703.
[4] Cervantes A, Elez E, Roda D, Ecsedy JA, Macarulla T, Venkatakrishnan K, et al.
Phase I pharmacokinetic/pharmacodynamic study of MLN8237 – an investiga-
tional, oral, selective, Aurora A Kinase inhibitor – in patients with advanced
solid tumors. Clin Cancer Res 2012;18:4764–74.
[5] Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K,
et al. Phase I study of Aurora A kinase inhibitor MLN8237 in advanced solid
tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of
two oral formulations. Clin Cancer Res 2012;18:4775–84.
[6] Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al.
Revised recommendations of the International Working Group for diagnosis,
standardization of response criteria, treatment outcomes, and reporting
standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol
2003;21:4642–9.
[7] Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer
SD, et al. Clinical application and proposal for modiﬁcation of the Interna-
tional Working Group (IWG) response criteria in myelodysplasia. Blood
2006;108:419–25.
[8] Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al.
Aurora-A and an interacting activator, the LIM protein Ajuba, are required for
mitotic commitment in human cells. Cell 2003;114:585–98.
[9] Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase
inhibitors: a review. Oncologist 2009;14:780–93.
[10] Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors – rising
stars in cancer therapeutics. Mol Cancer Ther 2010;9:268–78.
S.L. Goldberg et al. / Leukemia Research Reports 3 (2014) 58–61 61
